Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: Focus on the cancer hallmark of tumor angiogenesis

Carcinogenesis

Volumn 36, Issue , 2015, Pages S184-S202

  Hu, Zhiwei ^v   Brooks, Samira A ^a   Dormoy, Valérian ^b,c   Hsu, Chia Wen ^d   Hsu, Hsue Yin ^e   Lin, Liang Tzung ^f   Massfelder, Thierry ^b   Kimryn Rathmell, W ^a   Xia, Menghang ^d   Al Mulla, Fahd ^e   Al Temaimi, Rabeah ^g   Amedei, Amedeo ^h   Brown, Dustin G ⁱ   Prudhomme, Kalan R ^j   Colacci, Annamaria ^k   Hamid, Roslida A ^l   Mondello, Chiara ^m   Raju, Jayadev ⁿ   Ryan, Elizabeth P ⁱ   Woodrick, Jordan ^o   Ivana Scovassi, A ^m   Singh, Neetu ^p   Vaccari, Monica ^k   Roy, Rabindra ^o   Forte, Stefano ^q   Memeo, Lorenzo ^q   Salem, Hosni K ^r   Lowe, Leroy ^s   Jensen, Lasse ^t   Bisson, William H ^j   Kleinstreuer, Nicole ^u   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e TZU CHI UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g KUWAIT UNIVERSITY   (Kuwait)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ Department of Ecosystem Science and Sustainability   (United States)

^j OREGON STATE UNIVERSITY   (United States)

^k Center for Environmental Carcinogenesis and Risk Assessment   (Italy)

^l UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^m CNR   (Italy)

ⁿ TOXICOLOGY RESEARCH DIVISION   (Canada)

^o GEORGETOWN UNIVERSITY   (United States)

^p KING GEORGE'S MEDICAL UNIVERSITY   (India)

^q Department of Medical Oncology   (Italy)

^r CAIRO UNIVERSITY   (Egypt)

^s Getting to Know Cancer   (Canada)

^t LINKÖPING UNIVERSITY   (Sweden)

^u INTEGRATED LABORATORY SYSTEMS   (United States)

^v THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CARCINOGEN; CIGARETTE SMOKE; ENVIRONMENTAL CHEMICAL; NICOTINE; THROMBOPLASTIN; VASCULOTROPIN RECEPTOR; DANGEROUS GOODS; BIPHENYL; CHLOROTHALONIL; DINICONAZOLE; PERFLUOROOCTANESULFONIC ACID; PESTICIDE; TRIBUTYLTIN CHLORIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; ZIRAM;

ANGIOGENESIS; ANGIOGENESIS ASSAY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); BIOLOGICAL ACTIVITY; CARCINOGENICITY; RISK ASSESSMENT; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CARCINOGENESIS; CARCINOGENS, ENVIRONMENTAL; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84937695441     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv036     Document Type: Review

References (367)

1. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
2. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
3. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
4. Carmeliet, P. et al. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298-307.
5. Ferrara, N. et al. (2005) Angiogenesis as a therapeutic target. Nature, 438, 967-974.
6. Folkman, J. (2001) Angiogenesis-dependent diseases. Semin. Oncol., 28, 536-542.
7. Folkman, J. (2003) Angiogenesis inhibitors: a new class of drugs. Cancer Biol. Ther., 2(4 suppl. 1), S127-S133.
8. Cao, Y. et al. (2011) Forty-year journey of angiogenesis translational research. Sci. Transl. Med., 3, 114rv3.
9. Siemann, D.W. et al. (2005) Differentiation and definition of vasculartargeted therapies. Clin. Cancer Res., 11, 416-420.
10. Thorpe, P.E. (2004) Vascular targeting agents as cancer therapeutics. Clin. Cancer Res., 10, 415-427.
11. Patterson, D.M. et al. (2007) Vascular damaging agents. Clin. Oncol. (R. Coll. Radiol)., 19, 443-456.
12. Hu, Z. et al. (1999) Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc. Natl. Acad. Sci. USA, 96, 8161-8166.
13. Hu, Z. et al. (2001) Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc. Natl. Acad. Sci. USA, 98, 12180-12185.
14. Hu, Z. et al. (2010) Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunol., 11, 49.
15. van Heeckeren, W.J. et al. (2007) Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr. Opin. Hematol., 14, 468-480.
16. Bair, S.M. et al. (2013) Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc. Med., 23, 104-113.
17. Ellis, L.M. et al. (2008) VEGF-targeted therapy: mechanisms of antitumour activity. Nat. Rev. Cancer, 8, 579-591.
18. Muncke, J. (2011) Release of chemicals from plastics: lessons from food contact with plastics. Integr. Environ. Assess. Manag., 7, 688-690.
19. Hecht, S.S. (2012) Lung carcinogenesis by tobacco smoke. Int. J. Cancer, 131, 2724-2732.
20. Letašiová, S. et al. (2012) Bladder cancer, a review of the environmental risk factors. Environ. Health, 11 (suppl. 1), S11.
21. Loeb, L.A. et al. (1984) Smoking and lung cancer: an overview. Cancer Res., 44(12 Pt 1), 5940-5958.
22. Pogribny, I.P. et al. (2013) Environmental toxicants, epigenetics, and cancer. Adv. Exp. Med. Biol., 754, 215-232.
23. Sankpal, U.T. et al. (2012) Environmental factors in causing human cancers: emphasis on tumorigenesis. Tumour Biol., 33, 1265-1274.
24. Torti, S.V. et al. (2013) Iron and cancer: more ore to be mined. Nat. Rev. Cancer, 13, 342-355.
25. Vandenberg, L.N. (2014) Low-dose effects of hormones and endocrine disruptors. Vitam. Horm., 94, 129-165.
26. Collotta, M. et al. (2013) Epigenetics and pesticides. Toxicology, 307, 35-41.
27. Cao, Y. (2005) Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer, 5, 735-743.
28. Risau, W. (1997) Mechanisms of angiogenesis. Nature, 386, 671-674.
29. Chung, A.S. et al. (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer, 10, 505-514.
30. Potente, M. et al. (2011) Basic and therapeutic aspects of angiogenesis. Cell, 146, 873-887.
31. Weis, S.M. et al. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359-1370.
32. Jain, R.K. et al. (2012) SnapShot: Tumor angiogenesis. Cell, 149, 1408-1408.e1.
33. Welti, J. et al. (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest., 123, 3190-3200.
34. Kaelin, W.G. Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer, 8, 865-873.
35. Semenza, G.L. (2009) Regulation of cancer cell metabolism by hypoxiainducible factor 1. Semin. Cancer Biol., 19, 12-16.
36. Harris, A.L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
37. Lewis, C.E. et al. (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res., 67, 8429-8432.
38. Dvorak, H.F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 315, 1650-1659.
39. Xue, Y. et al. (2012) PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med., 18, 100-110.
40. Avraamides, C.J. et al. (2008) Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer, 8, 604-617.
41. Weis, S.M. et al. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359-1370.
42. Singh, S. et al. (2007) Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev., 26, 453-467.
43. van Hinsbergh, V.W. et al. (2006) Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol., 26, 716-728.
44. Wang, S.S. et al. (2009) AngiomiRs-Key regulators of angiogenesis. Curr. Opin. Genet. Dev., 19, 205-211.
45. Bao, L. et al. (2013) MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. 2013 337(2):226-36.
46. Nagy, J.A. et al. (2007) VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol., 2, 251-275.
47. Jain, R.K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
48. Smith, N.R. et al. (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res., 16, 3548-3561.
49. Christofori, G. et al. (1995) Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol., 9, 1760-1770.
50. Witmer, A.N. et al. (2002) Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J. Histochem. Cytochem., 50, 767-777.
51. Semeraro, N. et al. (1997) Tissue factor in health and disease. Thromb. Haemost., 78, 759-764.
52. Folkman, J. (1996) Tumor angiogenesis and tissue factor. Nat. Med., 2, 167-168.
53. Rickles, F.R. et al. (2001) The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int. J. Hematol., 73, 145-150.
54. Fernandez, P.M. et al. (2002) Tissue factor and angiogenesis in cancer. Curr. Opin. Hematol., 9, 401-406.
55. Pawlinski, R. et al. (2004) Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb. Haemost., 92, 444-450.
56. Rak, J. et al. (2006) Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost., 32, 54-70.
57. Fisher, K.L. et al. (1987) Cloning and expression of human tissue factor cDNA. Thromb. Res., 48, 89-99.
58. Morrissey, J.H. et al. (1987) Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell, 50, 129-135.
59. Spicer, E.K. et al. (1987) Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc. Natl. Acad. Sci. USA, 84, 5148-5152.
60. Konigsberg, W.H. et al. (1988) Molecular cloning of the cDNA for human tissue factor. Cell, 52, 639-640.
61. O'Hara, P.J. et al. (1987) Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc. Natl. Acad. Sci. USA, 84, 5158-5162.
62. Idusogie, E. et al. (1996) Characterization of a cDNA encoding murine coagulation factor VII. Thromb. Haemost., 75, 481-487.
63. Nemerson, Y. (1983) Regulation of the initiation of coagulation by factor VII. Haemostasis, 13, 150-155.
64. Contrino, J. et al. (1996) In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat. Med., 2, 209-215.
65. Duanmu, J. et al. (2011) Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. Br. J. Cancer, 104, 1401-1409.
66. Shoji, M. et al. (1998) Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am. J. Pathol., 152, 399-411.
67. Gabrilovich, D.I. et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2, 1096-1103.
68. Goel, H.L. et al. (2013) VEGF targets the tumour cell. Nat. Rev. Cancer, 13, 871-882.
69. Yao, X.H. et al. (2008) Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J. Pathol., 215, 369-376.
70. Abdulkadir, S.A. et al. (2000) Tissue factor expression and angiogenesis in human prostate carcinoma. Hum. Pathol., 31, 443-447.
71. Zucker, S. et al. (1998) Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int. J. Cancer, 75, 780-786.
72. Hu, Z. et al. (2010) Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer, 10, 235.
73. Hu, Z. (2011) Factor VII-targeted photodynamic therapy for breast cancer and its therapeutic potential for other solid cancers and leukemia. Breast Cancer - Current and Alternative Therapeutic Modalities, Prof. Esra Gunduz (Ed.), pp.175-196. ISBN: 978-953-307-776-5, InTech, doi:10.5772/20398.
74. Ruf, W. et al. (2010) Tissue factor in cancer progression and angiogenesis. Thromb. Res., 125 (suppl. 2), S36-S38.
75. Belting, M. et al. (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat. Med., 10, 502-509.
76. Fernandez, P.M. et al. (2004) Tissue factor and fibrin in tumor angiogenesis. Semin. Thromb. Hemost., 30, 31-44.
77. Versteeg, H.H. et al. (2003) Tissue factor signal transduction in angiogenesis. Carcinogenesis, 24, 1009-1013.
78. Kleinstreuer, N.C. et al. (2013) In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis. Toxicol. Sci., 131, 40-55.
79. Vicari, A.P. et al. (2002) Chemokines in cancer. Cytokine Growth Factor Rev., 13, 143-154.
80. Romagnani, P. et al. (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol., 25, 201-209.
81. Horowitz, N.A. et al. (2011) Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood, 118, 2889-2895.
82. Liu, P.L. et al. (2010) Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol. Carcinog., 49, 874-881.
83. Tang, X. et al. (2012) p53 is an important regulator of CCL2 gene expression. Curr. Mol. Med., 12, 929-943.
84. Lin, T.H. et al. (2013) CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim. Biophys. Acta, 1830, 4917-4927.
85. Gorgoulis, V.G. et al. (2003) p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. EMBO J., 22, 1567-1578.
86. Zhang, H.M. et al. (2005) Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression. Mol. Cell. Biol., 25, 6247-6258.
87. O'Donnell, E.F. et al. (2014) The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell Death Dis., 5, e1038.
88. Kung, T. et al. (2009) The aryl hydrocarbon receptor (AhR) pathway as a regulatory pathway for cell adhesion and matrix metabolism. Biochem. Pharmacol., 177, 11.
89. Dietrich, C. et al. (2010) The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis, 31, 1319-1328.
90. Andrysík, Z. et al. (2007) The aryl hydrocarbon receptor-dependent deregulation of cell cycle control induced by polycyclic aromatic hydrocarbons in rat liver epithelial cells. Mutat. Res., 615, 87-97.
91. Weiss, C. et al. (2008) TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A. Oncogene, 27, 2198-2207.
92. Roman, A.C. et al. (2009) Dioxin receptor deficiency impairs angiogenesis by a mechanism involving VEGF-A depletion in the endothelium and transforming growth factor-beta overexpression in the stroma. J. Biol. Chem., 284, 25135-25148.
93. Feng, S. et al. (2013) Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta, 1836, 14.
94. Huang, H.C. et al. (2013) UVB irradiation regulates ERK1/2- and p53-dependent thrombomodulin expression in human keratinocytes. PLoS One, 8, e67632.
95. Kumar, A. et al. (2011) p53 impairs endothelial function by transcriptionally repressing Kruppel-like factor 2. Arterioscler. Thromb. Vasc. Biol., 31, 133-141.
96. Maekita, T. et al. (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res., 12(3 Pt 1), 989-995.
97. Lengauer, C. et al. (1997) DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl. Acad. Sci. USA, 94, 2545-2550.
98. Ikezoe, T. et al. (2012) Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler. Thromb. Vasc. Biol., 32, 2259-2270.
99. Pickard, A. et al. (2012) Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion. EMBO J., 31, 3092-3103.
100. Kim, S. et al. (2008) Basal and UV-induced MMP-1 expression are inhibited by p53 in human dermal fibroblasts. Exp. Dermatol., 17, 939-945.
101. Wu, Y.H. et al. (2010) p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression. Cancer Res., 70, 10422-10432.
102. Singh, P.K. et al. (2008) Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J. Biol. Chem., 283, 26985-26995.
103. Gopinath, S. et al. (2010) Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation. PLoS One, 5, e11668.
104. Doll, R. (1986) Tobacco: an overview of health effects. IARC Scientific Publications, pp. 11-22.
105. Costa, F. et al. (2009) Nicotine: a pro-angiogenic factor. Life Sci., 84, 785-790.
106. Hecht, S.S. et al. (1975) Chemical studies on tobacco smoke. XXXIII. N' -nitrosonornicotine in tobacco: analysis of possible contributing factors and biologic implications. J. Natl. Cancer Inst., 54, 1237-1244.
107. Liu, E.S. et al. (2003) Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis, 24, 1407-1413.
108. Zhu, B.Q. et al. (2003) Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell, 4, 191-196.
109. Wang, Y.H. et al. (2013) Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. J. Hazard. Mater 262:1139-46.
110. Shin, V.Y. et al. (2004) Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis, 25, 2487-2495.
111. Zhang, Q. et al. (2007) Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin. Cancer Res., 13, 4686-4694.
112. Park, Y.J. et al. (2008) Effect of nicotine on human umbilical vein endothelial cells (HUVECs) migration and angiogenesis. Vascul. Pharmacol., 49, 32-36.
113. Heeschen, C. et al. (2001) Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med., 7, 833-839.
114. Wong, H.P. et al. (2007) Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol. Sci., 97, 279-287.
115. Mousa, S. et al. (2006) Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J. Cell. Biochem., 97, 1370-1378.
116. Martin, J.W. et al. (2009) The multiple faces of nicotine and its implications in tissue and wound repair. Exp. Dermatol., 18, 497-505.
117. Kao, Y.H. et al. (2003) Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem. Res. Toxicol., 16, 460-468.
118. Klei, L.R. et al. (2008) Positive signaling interactions between arsenic and ethanol for angiogenic gene induction in human microvascular endothelial cells. Toxicol. Sci., 102, 319-327.
119. Straub, A.C. et al. (2009) Arsenic requires sphingosine-1-phosphate type 1 receptors to induce angiogenic genes and endothelial cell remodeling. Am. J. Pathol., 174, 1949-1958.
120. Meng, D. et al. (2010) Arsenic promotes angiogenesis in vitro via a heme oxygenase-1-dependent mechanism. Toxicol. Appl. Pharmacol., 244, 291-299.
121. Straub, A.C. et al. (2007) Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol. Appl. Pharmacol., 222, 327-336.
122. Xu, X. et al. (2009) Diesel exhaust exposure induces angiogenesis. Toxicol. Lett., 191, 57-68.
123. Andersson, H. et al. (2012) Proangiogenic effects of environmentally relevant levels of bisphenol A in human primary endothelial cells. Arch. Toxicol., 86, 465-474.
124. Bredow, S. et al. (2007) Subchronic inhalation of soluble manganese induces expression of hypoxia-associated angiogenic genes in adult mouse lungs. Toxicol. Appl. Pharmacol., 221, 148-157.
125. Ishimura, R. et al. (2009) Dioxin-induced toxicity on vascular remodeling of the placenta. Biochem. Pharmacol., 77, 660-669.
126. Halin, C. et al. (2008) Chapter 1. Inflammation, angiogenesis, and lymphangiogenesis. Methods Enzymol., 445, 1-25.
127. Tice, R.R. et al. (2013) Improving the human hazard characterization of chemicals: a Tox21 update. Environ. Health Perspect., 121, 756-765.
128. Kavlock, R. et al. (2012) Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol., 25, 1287-1302.
129. Martin, M.T. et al. (2009) Profiling the reproductive toxicity of chemicals from multigeneration studies in the toxicity reference database. Toxicol. Sci., 110, 181-190.
130. Judson, R.S. et al. (2010) In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect., 118, 485-492.
131. Dairkee, S.H. et al. (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis, 34, 703-712.
132. Goldman, J.M. et al. (2004) Methoxychlor-induced alterations in the histological expression of angiogenic factors in pituitary and uterus. J. Mol. Histol., 35, 363-375.
133. Qian, Y. et al. (2010) Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. J. Toxicol. Environ. Health. A, 73, 819-836.
134. Zhang, Y.H. et al. (2013) Mechanism of perfluorooctanesulfonate (PFOS)-induced apoptosis in the immunocyte. J. Immunotoxicol., 10, 49-58.
135. Jessen-Eller, K. et al. (2002) A new invertebrate member of the p53 gene family is developmentally expressed and responds to polychlorinated biphenyls. Environ. Health Perspect., 110, 377-385.
136. Taylor, T.R. et al. (2011) Ziram activates mitogen-activated protein kinases and decreases cytolytic protein levels in human natural killer cells. Toxicol. Mech. Methods, 21, 577-584.
137. Wu, P.Y. et al. (2013) Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells. Biochem. Biophys. Res. Commun., 437, 440-445.
138. Madri, J.A. et al. (1986) Endothelial cell-matrix interactions: in vitro models of angiogenesis. J. Histochem. Cytochem., 34, 85-91.
139. Carmeliet, P. et al. (1998) Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc. Res., 39, 8-33.
140. Vailhé, B. et al. (2001) In vitro models of vasculogenesis and angiogenesis. Lab. Invest., 81, 439-452.
141. Bernardini, G. et al. (2004) In vitro and in vivo models to study chemokine regulation of angiogenesis. Methods Mol. Biol., 239, 223-232.
142. Radovanovic, I. et al. (2004) Angiogenesis in transgenic models of multistep angiogenesis. Cancer Treat. Res., 117, 97-114.
143. Hoang, M.V. et al. (2005) In vivo and in vitro models of Mammalian angiogenesis. Methods Mol. Biol., 294, 269-285.
144. Norrby, K. (2006) In vivo models of angiogenesis. J. Cell. Mol. Med., 10, 588-612.
145. Ucuzian, A.A. et al. (2007) In vitro models of angiogenesis. World J. Surg., 31, 654-663.
146. Deryugina, E.I. et al. (2008) Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. Methods Enzymol., 444, 21-41.
147. Shiba, Y. et al. (2008) Models for the study of angiogenesis. Curr. Pharm. Des., 14, 371-377.
148. Jensen, L.D. et al. (2009) In vivo angiogenesis and lymphangiogenesis models. Curr. Mol. Med., 9, 982-991.
149. Qutub, A.A. et al. (2009) Multiscale models of angiogenesis. IEEE Eng. Med. Biol. Mag., 28, 14-31.
150. Eklund, L. et al. (2013) Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol. Oncol., 7, 259-282.
151. Morin, K.T. et al. (2013) In vitro models of angiogenesis and vasculogenesis in fibrin gel. Exp Cell Res 319(16):2409-17.
152. Swartz, M.A. et al. (2012) Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res., 72, 2473-2480.
153. Sounni, N.E. et al. Targeting the tumor microenvironment for cancer therapy. Clin. Chem., 59, 85-93.
154. Shang, B. et al. (2012) Deciphering the key features of malignant tumor microenvironment for anti-cancer therapy. Cancer Microenviron., 5, 211-223.
155. Kwee, B.J. et al. (2014) Manipulating the intersection of angiogenesis and inflammation. Ann. Biomed. Eng.
156. Schweighofer, B. et al. (2009) The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb. Haemost., 102, 544-554.
157. Kobayashi, H. et al. (2009) Angiogenesis links chronic inflammation with cancer. Methods Mol. Biol., 511, 185-191.
158. Alfonso, L. et al. (2014) Molecular targets of aspirin and cancer prevention. Br. J. Cancer, 111, 61-67.
159. Gronich, N. et al. (2013) Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat. Rev. Clin. Oncol., 10, 625-642.
160. Borthwick, G.M. et al. (2006) Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J., 20, 2009-2016.
161. Etulain, J. et al. (2013) Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br. J. Pharmacol., 170, 255-265.
162. Singh, A.V. et al. (2006) Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res., 66, 1851-1858.
163. Kim, E.Y. et al. (2008) A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Biochem. Biophys. Res. Commun., 377, 1288-1293.
164. Peterson, K.J. et al. (2008) A fluorescence polarization assay for identifying ligands that bind to vascular endothelial growth factor. Anal. Biochem., 378, 8-14.
165. Wang, K. et al. (2011) Development of an AlphaScreen-based highthroughput screening assay for inhibitors of human vascular endothelial growth factor receptor-3. J. Immunoassay Immunochem., 32(3):219-232.
166. Moshinsky, D.J. et al. (2003) A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. J. Biomol. Screen., 8, 447-452.
167. Santos, A.F. et al. (2008) Angiogenesis: an improved in vitro biological system and automated image-based workflow to aid identification and characterization of angiogenesis and angiogenic modulators. Assay Drug Dev. Technol., 6, 693-710.
168. Wang, H.S. et al. (2004) A simple quantitative method for evaluation of angiogenesis activity. Assay Drug Dev. Technol., 2(1):31-38.
169. Reed, M.J. et al. (2007) Culture of murine aortic explants in 3-dimensional extracellular matrix: a novel, miniaturized assay of angiogenesis in vitro. Microvasc. Res., 73, 248-252.
170. Sanz, L. et al. (2002) Development of a computer-assisted highthroughput screening platform for anti-angiogenic testing. Microvasc. Res., 63, 335-339.
171. Yauch, R.L. et al. (2004) Transcriptional-based screens for pathwayspecific, high-throughput target discovery in endothelial cells. J. Biomol. Screen., 9, 704-711.
172. Bischel, L.L. et al. (2013) Tubeless microfluidic angiogenesis assay with three-dimensional endothelial-lined microvessels. Biomaterials, 34(5):1471-1477.
173. Yarrow, J.C. et al. (2004) A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol., 4, 21.
174. Kumar, N. et al. (2006) A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. Biophys. J., 91, L32-L34.
175. Huynh, Q.K. et al. (2011) Screening and identification of a novel class of TGF-beta type 1 receptor kinase inhibitor. J. Biomol. Screen., 16, 724-33.
176. Kung, A.L. et al. (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell, 6, 33-43.
177. Lee, Y. et al. (2004) High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. J. Biomol. Screen., 9, 687-694.
178. Staton, C.A. et al. (2009) A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol., 90, 195-221.
179. Evensen, L. et al. (2010) A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry. A, 77, 41-51.
180. Ji, D.B. et al. (2008) Establishment of a cell-based assay to screen regulators of the hypoxia-inducible factor-1-dependent vascular endothelial growth factor promoter. Biol. Pharm. Bull., 31, 2255-2259.
181. Johnson, R.L. et al. (2009) A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries. Mol. Biosyst., 5, 1039-1050.
182. Xia, M. et al. (2009) Identification of chemical compounds that induce HIF-1alpha activity. Toxicol. Sci., 112, 153-163.
183. Smirnova, N.A. et al. (2010) Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation. Chem. Biol., 17, 380-391.
184. Miller, S.C. et al. (2010) Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem. Pharmacol., 79, 1272-1280.
185. Takahashi, T. et al. (2011) An in vitro test to screen skin sensitizers using a stable THP-1-derived IL-8 reporter cell line, THP-G8. Toxicol. Sci., 124, 359-369.
186. Cash, J.N. et al. (2013) Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A. J. Biomol. Screen.
187. Li, X. et al. (2009) Identification of upregulators of BMP2 expression via high-throughput screening of a synthetic and natural compound library. J. Biomol. Screen., 14, 1251-1256.
188. Shukla, S.J. et al. (2010) The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov. Today, 15, 997-1007.
189. Attene-Ramos, M.S. et al. (2013) The Tox21 robotic platform for the assessment of environmental chemicals - from vision to reality. Drug Discov. Today.
190. Dejardin, E. (2006) The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol., 72, 1161-1179.
191. Chen, L.M. et al. (2011) RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J. Cell. Biochem., 112, 933-941.
192. Liu, S.Q. et al. (2013) Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules. Int. J. Oncol., 42, 617-626.
193. Madhavan, M. et al. (2002) Down regulation of endothelial adhesion molecules in node positive breast cancer: possible failure of host defence mechanism. Pathol. Oncol. Res., 8, 125-128.
194. Ding, Y.B. et al. (2003) Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J. Gastroenterol., 9, 1409-1414.
195. Heidemann, J. et al. (2006) Expression of vascular cell adhesion molecule-1 (CD 106) in normal and neoplastic human esophageal squamous epithelium. Int. J. Oncol., 28, 77-85.
196. Slack-Davis, J.K. et al. (2009) Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res., 69, 1469-1476.
197. Yepuri, G. et al. (2012) Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging. Aging Cell, 11, 1005-1016.
198. Bose, A. et al. (2013) Tumor-derived vascular pericytes anergize Th cells. J. Immunol., 191, 971-981.
199. Petro, M. et al. (2013) Cutaneous tumors cease CXCL9/Mig production as a result of IFN-γ-mediated immunoediting. J. Immunol., 190, 832-841.
200. Kryczek, I. et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 114, 1141-1149.
201. Chang, K.P. et al. (2013) Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol., 49, 802-807.
202. Walser, T.C. et al. (2007) Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J. Immunother., 30, 490-498.
203. Reckamp, K.L. et al. (2007) Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J. Immunother., 30, 417-424.
204. Bronger, H. et al. (2012) Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res., 14, R30.
205. O'Garra, A. et al. (2012) Editorial overview. Curr. Opin. Immunol., 24, 361-363.
206. Musah, S. et al. (2012) Tumor necrosis factor-α mediates interactions between macrophages and epithelial cells underlying proinflammatory gene expression induced by particulate matter. Toxicology, 299, 125-132.
207. Wong, J.L. et al. (2013) IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res., 73, 4653-4662.
208. Hanly, A.M. et al. (2006) Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br. J. Cancer, 94, 1320-1325.
209. Chen, L.M. et al. (2013) Thrombomodulin mediates the progression of epithelial ovarian cancer cells. Tumour Biol., 34, 3743-3751.
210. Tai, C.J. et al. (2014) Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial-mesenchymal transition biomarkers. Tumour Biol., 35, 47-54.
211. Rajashekhar, G. et al. (2012) Soluble thrombomodulin reduces inflammation and prevents microalbuminuria induced by chronic endothelial activation in transgenic mice. Am. J. Physiol. Renal Physiol., 302, F703-F712.
212. Joven, J. et al. (2013) Multifunctional targets of dietary polyphenols in disease: a case for the chemokine network and energy metabolism. Food Chem. Toxicol., 51, 267-279.
213. Hacke, K. et al. (2010) Regulation of MCP-1 chemokine transcription by p53. Mol. Cancer, 9, 82.
214. Redon, C.E. et al. (2010) Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc. Natl. Acad. Sci. USA, 107, 17992-17997.
215. Kudo-Saito, C. et al. (2013) CCL2 is critical for immunosuppression to promote cancer metastasis. Clin. Exp. Metastasis, 30, 393-405.
216. Huang, B. et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett., 252, 86-92.
217. Eugenin, E.A. et al. (2003) MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem., 85, 1299-1311.
218. Hu, W.T. et al. (2014) IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-κB and ERK1/2 signaling. Mol. Hum. Reprod., 20, 358-372.
219. Soria, G. et al. (2011) Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer, 11, 130.
220. Li, M.Q. et al. (2011) CD82 gene suppression in endometrial stromal cells leads to increase of the cell invasiveness in the endometriotic milieu. J. Mol. Endocrinol., 47, 195-208.
221. Izumi, K. et al. (2013) Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol. Med., 5, 1383-1401.
222. Karasawa, F. et al. (2012) Essential role of gastric gland mucin in preventing gastric cancer in mice. J. Clin. Invest., 122, 923-934.
223. Borsig, L. et al. (2014) Inflammatory chemokines and metastasis-tracing the accessory. Oncogene, 33, 3217-3224.
224. Fang, W. et al. (2005) The effects of polygoni multiflori total glycosides on the experimentally atherosclerotic formation in apoE-deficient mice. Zhongguo Zhong Yao Za Zhi, 30, 1542-1545.
225. Krutmann, J. et al. (1994) Evidence that DNA damage is a mediate in ultraviolet B radiation-induced inhibition of human gene expression: ultraviolet B radiation effects on intercellular adhesion molecule-1 (ICAM-1) expression. J. Invest. Dermatol., 102, 428-432.
226. Shirai, A. et al. (2003) Expression of intercellular adhesion molecule (ICAM)-1 in adenoid cystic carcinoma of the head and neck. Laryngoscope, 113, 1955-1960.
227. Gallaher, A.M. et al. (2013) Proteomic screening of human targets of viral microRNAs reveals functions associated with immune evasion and angiogenesis. PLoS Pathog., 9, e1003584.
228. Li, X. et al. (2010) The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood, 116, 2304-2314.
229. Usami, Y. et al. (2013) Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int. J. Cancer, 133, 568-578.
230. Schröder, C. et al. (2011) Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J. Cancer Res. Clin. Oncol., 137, 1193-1201.
231. Buitrago, D. et al. (2012) Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann. Surg. Oncol., 19, 973-980.
232. Ramer, R. et al. (2012) Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J., 26, 1535-1548.
233. Rafat, M. et al. (2012) Engineered endothelial cell adhesion via VCAM1 and E-selectin antibody-presenting alginate hydrogels. Acta Biomater., 8, 2697-2703.
234. Oberyszyn, T.M. et al. (1998) Beta2 integrin/ICAM-1 adhesion molecule interactions in cutaneous inflammation and tumor promotion. Carcinogenesis, 19, 445-455.
235. Chen, Q. et al. (2012) Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin. Cancer Res., 18, 5520-5525.
236. Grismayer, B. et al. (2012) Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes. Biol. Chem., 393, 1449-1455.
237. Shetty, S. et al. (2007) Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. Mol. Cell. Biol., 27, 5607-5618.
238. Shetty, P. et al. (2008) Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover. Am. J. Respir. Cell Mol. Biol., 39, 364-372.
239. Gupta, R. et al. (2011) Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo. Int. J. Oncol., 38, 973-983.
240. Wang, F. et al. (2011) Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. J. Med. Chem., 54, 7193-7205.
241. Hodjat, M. et al. (2013) Urokinase receptor mediates doxorubicininduced vascular smooth muscle cell senescence via proteasomal degradation of TRF2. J. Vasc. Res., 50, 109-123.
242. Bhandary, Y.P. et al. (2013) Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1. Am. J. Pathol., 183, 131-143.
243. Testa, J.E. et al. (1990) The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev., 9, 353-367.
244. Stahl, A. et al. (1994) Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res., 54, 3066-3071.
245. Cantero, D. et al. (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer, 75, 388-395.
246. Reuning, U. et al. (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int. J. Oncol., 13, 893-906.
247. Lund, I.K. et al. (2011) uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr. Drug Targets, 12, 1744-1760.
248. Noh, H. et al. (2013) Role of urokinase receptor in tumor progression and development. Theranostics, 3, 487-495.
249. Thunø, M. et al. (2009) suPAR: the molecular crystal ball. Dis. Markers, 27, 157-172.
250. Zhuang, T. et al. (2013) Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration. BMC Cancer, 13, 590.
251. Marcus, H.J. et al. (2010) In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J. Neurooncol., 97, 11-23.
252. Wapnir, I.L. et al. (1996) Collagen gene expression in the neomatrix of carcinoma of the breast. Invas. Metastasis, 16, 308-316.
253. Menke, A. et al. (2001) Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res., 61, 3508-3517.
254. Imamichi, Y. et al. (2007) Signaling pathways involved in collageninduced disruption of the E-cadherin complex during epithelialmesenchymal transition. Cells. Tissues. Organs, 185, 180-190.
255. Zhang, X. et al. (2013) Histone deacetylase inhibition downregulates collagen 3A1 in fibrotic lung fibroblasts. Int. J. Mol. Sci., 14, 19605-19617.
256. Boyd, A. et al. (2013) Quiescent innate response to infective filariae by human Langerhans cells suggests a strategy of immune evasion. Infect. Immun., 81, 1420-1429.
257. Srivastava, M.K. et al. (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One, 7, e40677.
258. Thakur, A. et al. (2013) Immunotherapy and immune evasion in prostate cancer. Cancers (Basel)., 5, 569-590.
259. Kryczek, I. et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 114, 1141-1149.
260. Lee, Y. et al. (2012) Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood, 119, 227-237.
261. Martins, V.L. et al. (2009) Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J. Cell Sci., 122(Pt 11), 1788-1799.
262. Jiang, Z. et al. (2010) CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol. Biol. Rep., 37, 3029-3036.
263. Kawada, K. et al. (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res., 64, 4010-4017.
264. Tannenbaum, C.S. et al. (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol., 161, 927-932.
265. Walser, T.C. et al. (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res., 66, 7.
266. Ling, C.C. et al. (2014) Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J. Hepatol., 60, 103-109.
267. Billottet, C. et al. (2013) CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim. Biophys. Acta, 1836, 287-295.
268. Nakayama, K. (2013) cAMP-response element-binding protein (CREB) and NF-κB transcription factors are activated during prolonged hypoxia and cooperatively regulate the induction of matrix metalloproteinase MMP1. J. Biol. Chem., 288, 22584-22595.
269. Radisky, D.C. et al. (2006) Matrix metalloproteinase-induced genomic instability. Curr. Opin. Genet. Dev., 16, 45-50.
270. Urtasun, R. et al. (2009) Reactive nitrogen species switch on early extracellular matrix remodeling via induction of MMP1 and TNFalpha. Gastroenterology, 136, 1410-22, e1.
271. Nutt, J.E. et al. (1998) Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br. J. Cancer, 78, 215-220.
272. Pritchard, S.C. et al. (2001) Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol. Rep., 8, 421-424.
273. Lu, X. et al. (2009) ADAMTS1 and MMP1 proteolytically engage EGFlike ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev., 23, 13.
274. Bao, W. et al. (2010) HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch. Biochem. Biophys., 499, 49-55.
275. Garamszegi, N. et al. (2012) Matrix metalloproteinase-1 contribution to sarcoma cell invasion. J. Cell. Mol. Med., 16, 1331-1341.
276. Liao, M. et al. (2012) Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma. Pathol. Oncol. Res., 18, 7.
277. Fanjul-Fernández, M. et al. (2013) Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J. Biol. Chem., 288, 14647-14656.
278. Al-Hassan, N.N. et al. (2012) Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia, 14, 259-270.
279. Reyes-Hernández, O.D. et al. (2009) Aromatic hydrocarbons upregulate glyceraldehyde-3-phosphate dehydrogenase and induce changes in actin cytoskeleton. Role of the aryl hydrocarbon receptor (AhR). Toxicology, 266, 30-37.
280. Marlowe, J.L. et al. (2005) Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell. Biochem., 96, 1174-1184.
281. Korkalainen, M. et al. (2012) induces genomic instability in mouse embryonic fibroblasts. PLoS One, 7, e37895.
282. Caruso, J.A. et al. (2006) Aryl hydrocarbon receptor modulation of tumor necrosis factor-alpha-induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8-independent. J. Biol. Chem., 281, 10954-10967.
283. Park, K.T. et al. (2005) The aryl hydrocarbon receptor predisposes hepatocytes to Fas-mediated apoptosis. Mol. Pharmacol., 67, 612-622.
284. Shervington, A. et al. (2007) Identification of a novel co-transcription of P450/1A1 with telomerase in A549. Genes Dev., 388, 7.
285. Sarkar, P. et al. (2006) Activation of telomerase in BeWo cells by estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin in co-operation with c-Myc. I. Int. J. Oncol., 28, 9.
286. Ray, S. et al. (2009) Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: a tumor promoting event. Biochem. Pharmacol., 77, 8.
287. Lahoti, T.S. et al. (2014) Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Pharmacol. Exp. Ther., 348, 236-245.
288. Budinsky, R.A. et al. (2014) Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study. Crit. Rev. Toxicol., 44, 83-119.
289. Goode, G.D. et al. (2013) Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line. Int. J. Cancer, 133, 2769-2780.
290. Pierre, S. et al. (2014) Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin. Toxicol. Sci., 137, 11.
291. Opitz, C.A. et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478, 197-203.
292. Hosokawa, S. et al. (1993) Hormonal disregulation mechanism in the rat thyroid tumor induced by diniconazole. J. Toxicol. Sci., 18, 11.
293. Koç, H. et al. (2012) Severe hepatotoxicity and acute renal failure caused by diniconazole. Clin. Res. Hepatol. Gastroenterol., 36, e104-e105.
294. Wang, X.F. et al. (2006) Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiol. Dis., 23, 198-205.
295. Gopinath, S. et al. (2011) Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma. Mol. Oncol., 5, 12.
296. Taylor, T.R. et al. (2011) Ziram activates mitogen-activated protein kinases and decreases cytolytic protein levels in human natural killer cells. Toxicol. Mech. Methods., 21, 8.
297. Scarabelli, L. et al. (1993) Relationship between poly(ADP-ribose) polymerase activity and DNA damage induced by zinc dithiocarbamates in mouse and rat liver. Mutat. Res., 302, 1-6.
298. Li, Q. et al. (2012) Mechanism of ziram-induced apoptosis in human natural killer cells. Int. J. Immunopathol. Pharmacol., 25, 883-891.
299. Coussens, L.M. et al. (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science, 339, 286-291.
300. Blog, D.N. (2012) Take action! New farm bill amendments attack your health and environment; beyond pesticides. Daily News Blog.
301. Cima, F. et al. (2008) Toxic effects of new antifouling compounds on tunicate haemocytes I. Sea-nine 211 and chlorothalonil. Aquat. Toxicol., 86, 299-312.
302. Pariseau, J. et al. (2011) Effects of pesticide compounds (chlorothalonil and mancozeb) and benzo[a]pyrene mixture on aryl hydrocarbon receptor, p53 and ubiquitin gene expression levels in haemocytes of soft-shell clams (Mya arenaria). Ecotoxicology, 20, 1765-1772.
303. Lebailly, P. et al. (1997) Assessment of DNA damage induced in vitro by etoposide and two fungicides (carbendazim and chlorothalonil) in human lymphocytes with the comet assay. Mutat. Res., 375, 205-217.
304. Greenlee, A.R. et al. (2004) Low-dose agrochemicals and lawn-care pesticides induce developmental toxicity in murine preimplantation embryos. Environ. Health Perspect., 112, 7.
305. Tessier, D.M. et al. (2001) Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides. Toxicol. Sci., 60, 6.
306. Wilkinson, C.F. et al. (1996) A mechanistic interpretation of the oncogenicity of chlorothalonil in rodents and an assessment of human relevance. Regul. Toxicol. Pharmacol., 24(1 Pt 1), 69-84.
307. Rencüzoğullari, E. et al. (2008) The effects of food protector biphenyl on sister chromatid exchange, chromosome aberrations, and micronucleus in human lymphocytes. Drug Chem. Toxicol., 31, 263-274.
308. Park, J.B. et al. (2012) Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway. Biol. Pharm. Bull., 35, 1614-1620.
309. Pisano, M. et al. (2007) Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol. Cancer Ther., 6, 3.
310. Holland, J.P. et al. (2013) Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors. Chem. Biodivers., 10, 18.
311. Brown, J.F. Jr et al. (2007) Polychlorinated biphenyls modulated tumorigenesis in Sprague Dawley rats: correlation with mixed function oxidase activities and superoxide (O2*) formation potentials and implied mode of action. Toxicol. Sci., 98(2):375-394.
312. Nozaki, S. et al. (2003) Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clin. Exp. Metastasis., 20, 6.
313. Shin, K.D. et al. (2005) Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J. Biol. Chem., 280, 10.
314. Hwang, E.S. et al. (2010) Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci. Biotechnol. Biochem., 74, 961-967.
315. Bunaciu, R.P. et al. (2007) The effect of dietary glycine on the hepatic tumor promoting activity of polychlorinated biphenyls (PCBs) in rats. Toxicology, 239, 147-155.
316. Yamada, S. et al. (2013) AMP-activated protein kinase-mediated glucose transport as a novel target of tributyltin in human embryonic carcinoma cells. Metallomics, 5, 484-491.
317. Isomura, M. et al. (2013) Tributyltin-induced endoplasmic reticulum stress and its Ca(2+)-mediated mechanism. Toxicol. Appl. Pharmacol., 272, 10.
318. Kirchner, S. et al. (2010) Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. Mol. Endocrinol., 24, 526-539.
319. Tsunoda, M. et al. (2006) Subacute administration of tributyltin chloride modulates neurotransmitters and their metabolites in discrete brain regions of maternal mice and their F1 offspring. Toxicol. Ind. Health, 22, 15-25.
320. Tiano, L. et al. (2001) DNA damage induced by organotins on troutnucleated erythrocytes. Appl. Organometal. Chem., 15, 6.
321. Mitra, S. et al. (2013) Tributyltin chloride induced testicular toxicity by JNK and p38 activation, redox imbalance and cell death in sertoligerm cell co-culture. Toxicology, 314, 12.
322. Zhang, J. et al. (2011) Tributyltin chloride results in dorsal curvature in embryo development of Sebastiscus marmoratus via apoptosis pathway. Chemosphere, 82, 437-442.
323. Nakatsu, Y. et al. (2007) Concentration dependence of the mechanisms of tributyltin-induced apoptosis. Toxicol. Sci., 97, 438-447.
324. Tiano, L. et al. (2003) Effect of tributyltin on trout blood cells: changes in mitochondrial morphology and functionality. Biochim. Biophys. Acta., 1640, 8.
325. Ishihara, Y. et al. (2012) Tributyltin induces oxidative stress and neuronal injury by inhibiting glutathione S-transferase in rat organotypic hippocampal slice cultures. Neurochem. Int., 60, 782-790.
326. Singh, T. et al. (2006) Microscopic, biochemical and physiological assessment of the effect of methylene bisthiocyanate on the sapstain fungus ophiostoma floccosum. Eur. J. Plant Pathol., 114, 12.
327. Thejass, P. et al. (2006) Antimetastatic activity of sulforaphane. Life Sci., 78, 8.
328. Jee, H.G. et al. (2011) Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro. Phytother. Res., 25, 6.
329. Xu, T. et al. (2012) Dual roles of sulforaphane in cancer treatment. Anticancer Agents Med. Chem., 12, 12.
330. Burka, L.T. (1993) NTP technical report on the toxicity studies of Methylene Bis(thiocyanate) (CAS No. 6317-18-6) Administered by Gavage to F344/N Rats and B6C3F1 Mice. Toxic. Rep. Ser., 32, 1-E7.
331. Bulger, W.H. et al. (1978) Interactions of methoxychlor, methoxychlor base-soluble contaminant, and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane with rat uterine estrogen receptor. J. Toxicol. Environ. Health, 4, 881-893.
332. Skinner, M.K. et al. (2011) Epigenetic transgenerational actions of endocrine disruptors. Reprod. Toxicol., 31, 337-343.
333. Symonds, D.A. et al. (2005) Methoxychlor induces proliferation of the mouse ovarian surface epithelium. Toxicol. Sci., 83, 8.
334. Hall, J.M. et al. (2013) Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol. Carcinog., 52, 715-725.
335. Shishodia, S. et al. (2005) N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res., 65, 9555-9565.
336. Dong, G.H. et al. (2012) Induction of p53-mediated apoptosis in splenocytes and thymocytes of C57BL/6 mice exposed to perfluorooctane sulfonate (PFOS). Toxicol. Appl. Pharmacol., 264, 292-299.
337. Eriksen, K.T. et al. (2010) Genotoxic potential of the perfluorinated chemicals PFOA, PFOS, PFBS, PFNA and PFHxA in human HepG2 cells. Mutat. Res., 700, 39-43.
338. Wang, X. et al. (2013) PFOS-induced apoptosis through mitochondrion-dependent pathway in human-hamster hybrid cells. Mutat. Res., 754, 51-57.
339. Lee, Y.J. et al. (2013) Perfluorooctane sulfonate-induced apoptosis of cerebellar granule cells is mediated by ERK 1/2 pathway. Chemosphere, 90, 1597-1602.
340. Elcombe, C.R. et al. (2012) Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology, 293, 16-29.
341. Fair, P.A. et al. (2011) Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice. J. Immunotoxicol., 8, 17-29.
342. Liao, Y. et al. (2012) Evaluation of cellular response to perfluorooctane sulfonate in human umbilical vein endothelial cells. Toxicol. In Vitro, 26, 421-428.
343. Betancourt, A.M. et al. (2012) Altered carcinogenesis and proteome in mammary glands of rats after prepubertal exposures to the hormonally active chemicals bisphenol a and genistein. J. Nutr., 142, 1382S-1388S.
344. Fillon, M. (2012) Getting it right: BPA and the difficulty proving environmental cancer risks. J. Natl. Cancer Inst., 104, 652-655.
345. Lee, S. et al. (2013) Neurotoxic effects of bisphenol AF on calciuminduced ROS and MAPKs. Neurotox. Res., 23, 249-259.
346. Pupo, M. et al. (2012) Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ. Health Perspect., 120, 1177-1182.
347. Zhu, H. et al. (2010) Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Oncol. Rep., 23, 129-139.
348. Jenkins, S. et al. (2011) Chronic oral exposure to bisphenol A results in a nonmonotonic dose response in mammary carcinogenesis and metastasis in MMTV-erbB2 mice. Environ. Health Perspect., 119, 1604-1609.
349. Derouiche, S. et al. (2013) Bisphenol A stimulates human prostate cancer cell migration via remodelling of calcium signalling. Springerplus, 2, 54.
350. Feng, Y. et al. (2012) Bisphenol AF may cause testosterone reduction by directly affecting testis function in adult male rats. Toxicol. Lett., 211, 201-209.
351. Pitot, H.C. et al. (1989) Regulation of the expression of some genes for enzymes of glutathione metabolism in hepatotoxicity and hepatocarcinogenesis. Toxicol. Appl. Pharmacol., 97, 23-34.
352. Stiborová, M. et al. (2002) Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res., 62, 5678-5684.
353. Stiborová, M. et al. (2009) Oxidation of the carcinogenic nonaminoazo dye 1-phenylazo-2-hydroxy-naphthalene (Sudan I) by cytochromes P450 and peroxidases: a comparative study. Interdiscip. Toxicol., 2, 195-200.
354. Ohno, M. et al. (2012) Sudan III dye strongly induces CYP1A1 mRNA expression in HepG2 cells. J. Biochem. Mol. Toxicol., 26, 7.
355. Elliott, B.M. et al. (1997) CI solvent yellow 14 shows activity in the bone marrow micronucleus assay in both the rat and mouse. Mutagenesis, 12, 255-258.
356. Pitot, H.C. et al. (1989) Critical parameters in the quantitation of the stages of initiation, promotion, and progression in one model of hepatocarcinogenesis in the rat. Toxicol. Pathol., 17(4 Pt 1), 594-611; discussion 611.
357. Gough, W. et al. (2011) A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assay. J. Biomol. Screen., 16, 155-63.
358. Wang, L. et al. (2008) An automatic and quantitative on-chip cell migration assay using self-assembled monolayers combined with real-time cellular impedance sensing. Lab Chip, 8, 872-878.
359. Nie, F.Q. et al. (2007) On-chip cell migration assay using microfluidic channels. Biomaterials, 28, 4017-4022.
360. Moody, M.D. et al. (2001) Array-based ELISAs for high-throughput analysis of human cytokines. Biotechniques, 31, 186-190, 192.
361. Xia, M. et al. (2009) Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. Mol. Cancer, 8, 117.
362. Hellweg, C.E. et al. (2003) Generation of stably transfected mammalian cell lines as fluorescent screening assay for NF-kappaB activation-dependent gene expression. J. Biomol. Screen., 8, 511-521.
363. Huang, H. et al. (2012) High-throughput screening for bioactive molecules using primary cell culture of transgenic zebrafish embryos. Cell Rep., 2, 695-704.
364. Kiss-Toth, E. et al. (2000) A novel mammalian expression screen exploiting green fluorescent protein-based transcription detection in single cells. J. Immunol. Methods, 239, 125-135.
365. Rapisarda, A. et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res., 62, 4316-4324.
366. Woldemichael, G.M. et al. (2006) Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. J. Biomol. Screen., 11, 678-687.
367. Zerwes, H.G. et al. (2002) A multiparameter screening assay to assess the cytokine-induced expression of endothelial cell adhesion molecules. Anal. Biochem., 304, 166-173.